A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intravenous Bolus Injection and Infusion for Subjects Undergoing Cardiac Echocardiography

NCT07740421 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiac Diseases

Interventions

DRUG: NH002 (Perflutren Lipid Microspheres) Injectable Suspension

Sponsor

Trust Bio-sonics, Inc.

Collaborators

[object Object]